{"id":682,"date":"2026-02-02T14:51:01","date_gmt":"2026-02-02T14:51:01","guid":{"rendered":"https:\/\/admarebio.com\/?page_id=682"},"modified":"2026-03-24T14:48:19","modified_gmt":"2026-03-24T14:48:19","slug":"actualites-et-perspectives","status":"publish","type":"page","link":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/","title":{"rendered":"Actualit\u00e9s et perspectives"},"content":{"rendered":"\n<div class=\"wp-block-cover alignfull is-style-bg-hex-pattern\" style=\"padding-top:var(--wp--preset--spacing--60);padding-right:var(--wp--preset--spacing--40);padding-bottom:var(--wp--preset--spacing--60);padding-left:var(--wp--preset--spacing--40);min-height:527px;aspect-ratio:unset;\"><img loading=\"lazy\" decoding=\"async\" width=\"2561\" height=\"1708\" class=\"wp-block-cover__image-background wp-image-956 size-full\" alt=\"\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/03\/Homepage-Gradient-flip-1.png\" data-object-fit=\"cover\" srcset=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/03\/Homepage-Gradient-flip-1.png 2561w, https:\/\/admarebio.com\/wp-content\/uploads\/2026\/03\/Homepage-Gradient-flip-1-1536x1024.png 1536w, https:\/\/admarebio.com\/wp-content\/uploads\/2026\/03\/Homepage-Gradient-flip-1-2048x1366.png 2048w\" sizes=\"auto, (max-width: 2561px) 100vw, 2561px\" \/><span aria-hidden=\"true\" class=\"wp-block-cover__background has-admare-blue-background-color has-background-dim-30 has-background-dim\"><\/span><div class=\"wp-block-cover__inner-container is-layout-flow wp-block-cover-is-layout-flow\">\n<div class=\"wp-block-group alignfull is-content-justification-left is-layout-constrained wp-container-core-group-is-layout-806bb2a1 wp-block-group-is-layout-constrained\">\n<h1 class=\"wp-block-heading alignwide has-h-2-font-size\" style=\"margin-bottom:0\">Actualit\u00e9s et perspectives<\/h1>\n<\/div>\n<\/div><\/div>\n\n\n\n<div class=\"wp-block-group alignfull is-layout-constrained wp-block-group-is-layout-constrained\"><div class=\"is-layout-flow wp-block-group filter-archive alignfull  post\">\n\t<div class=\"is-layout-flow wp-block-group filters alignfull has-white-background\" style=\" padding-right:var(--wp--preset--spacing--40);padding-left:var(--wp--preset--spacing--40)\">\n\t\t<div class=\"wp-block-group alignwide\" style=\"padding-top: var(--wp--preset--spacing--30);padding-bottom: var(--wp--preset--spacing--30); max-width: var(--wp--style--global--wide-size); margin: 0 auto !important\">\n\t\t\t<form style=\"margin-bottom: 0;\" id=\"filter-form\" method=\"get\" class=\"is-layout-flex wp-block-columns\" data-post-type=\"post\" data-template-block-id=\"936\" data-empty-message=\"No matches found. Try another filter.\">\n\t\t\t\n\t\t\t\t\t\t\t<div class=\"filter-taxonomy wp-block-column button-container\" id=\"category\">\n\t\t\t\t\t\t\t\t\t\t<div class=\"wp-block-buttons alignwide is-layout-flex\" style=\"gap: clamp(0.5rem, 0.02rem + 2.04vw, 1rem);\">\n\t\t\t\t\t\t<div class=\"wp-block-button is-style-filter default\" data-taxonomy=\"category\">\n\t\t\t\t\t\t\t<button type=\"submit\" name=\"category\" value=\"\" class=\"wp-block-button__link active\">\n\t\t\t\t\t\t\t\tVoir tout\t\t\t\t\t\t\t<\/button>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"wp-block-button is-style-filter\" data-term=\"actualites-dadmare\" data-taxonomy=\"category\">\n\t\t\t\t\t\t\t\t<button type=\"submit\" name=\"category\" value=\"actualites-dadmare\" class=\"wp-block-button__link \">\n\t\t\t\t\t\t\t\t\tActualit\u00e9s d\u2019adMare\t\t\t\t\t\t\t\t<\/button>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"wp-block-button is-style-filter\" data-term=\"actualites-des-compagnies-du-portefeuille\" data-taxonomy=\"category\">\n\t\t\t\t\t\t\t\t<button type=\"submit\" name=\"category\" value=\"actualites-des-compagnies-du-portefeuille\" class=\"wp-block-button__link \">\n\t\t\t\t\t\t\t\t\tActualit\u00e9s des compagnies du portefeuille\t\t\t\t\t\t\t\t<\/button>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"wp-block-button is-style-filter\" data-term=\"perspectives-dadmare\" data-taxonomy=\"category\">\n\t\t\t\t\t\t\t\t<button type=\"submit\" name=\"category\" value=\"perspectives-dadmare\" class=\"wp-block-button__link \">\n\t\t\t\t\t\t\t\t\tPerspectives d&#8217;adMare\t\t\t\t\t\t\t\t<\/button>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\n\t\t\t<input type=\"hidden\" name=\"_orderby\" id=\"orderby\" value=\"post_date\">\n\t\t\t<input type=\"hidden\" name=\"_order\" id=\"order\" value=\"desc\">\n\t\t\t<input type=\"hidden\" name=\"_paged\" id=\"paged\" value=\"1\">\n\t\t\t<input type=\"hidden\" name=\"_per_page\" id=\"per_page\" value=\"60\">\n\t\t\t<input class=\"screen-reader-text\" type=\"submit\" value=\"Submit\">\n\t\t\t<\/form>\n\t\t<\/div>\n\t<\/div>\n\n\t<div class=\"is-layout-flow wp-block-query alignwide has-glacier-background-color\" style=\"padding-bottom: var(--wp--preset--spacing--70); padding-top: var(--wp--preset--spacing--60);padding-bottom: var(--wp--preset--spacing--60);padding-right:var(--wp--preset--spacing--40);padding-left:var(--wp--preset--spacing--40);margin-top: 0;\">\n\t\t<ul class=\"is-layout-flow is-flex-container columns-4 alignwide wp-block-post-template archive-items\" style=\"max-width: var(--wp--style--global--wide-size); margin: 0 auto !important\">\n\t\t\t<li class=\"wp-block-post post-2507 post type-post status-publish format-standard has-post-thumbnail hentry category-perspectives-dadmare\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/le-canada-a-la-science-a-t-il-la-strategie-pour-devenir-une-puissance-des-sciences-de-la-vie\/\" title=\"Le Canada a la science. A-t-il la strat\u00e9gie pour devenir une puissance des sciences de la vie?\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1197\" height=\"628\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/07\/annonce-1-1784646780.png\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Perspectives d&#039;adMare \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">07.21.2026<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">Le Canada a la science. A-t-il la strat\u00e9gie pour devenir une puissance des sciences de la vie?<\/p>\n    <\/a>\n\n<\/div><\/li><li class=\"wp-block-post post-2406 post type-post status-publish format-standard has-post-thumbnail hentry category-actualites-dadmare\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/linstitut-pour-cadres-superieurs-dadmare-ouvre-les-candidatures-pour-sa-neuvieme-cohorte\/\" title=\"L\u2019Institut pour cadres sup\u00e9rieurs d\u2019adMare ouvre les candidatures pour sa neuvi\u00e8me cohorte\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1199\" height=\"628\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/07\/annonce-1781557657.png\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Actualit\u00e9s d\u2019adMare \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">06.16.2026<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">L\u2019Institut pour cadres sup\u00e9rieurs d\u2019adMare ouvre les candidatures pour sa neuvi\u00e8me cohorte<\/p>\n    <\/a>\n\n<\/div><\/li><li class=\"wp-block-post post-2400 post type-post status-publish format-standard has-post-thumbnail hentry category-actualites-des-compagnies-du-portefeuille\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/voxcell-bioinnovation-et-admare-bioinnovations-sassocient-pour-faire-progresser-le-developpement-de-nouvelles-therapies-a-base-danticorps-grace-a-une-plateforme-de-tissus-vascularise\/\" title=\"VoxCell BioInnovation et adMare BioInnovations s\u2019associent pour faire progresser le d\u00e9veloppement de nouvelles th\u00e9rapies \u00e0 base d\u2019anticorps gr\u00e2ce \u00e0 une plateforme de tissus vascularis\u00e9s repr\u00e9sentative de la physiologie humaine\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"799\" height=\"418\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/07\/1778682975191-1781646728-1.jpg\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Actualit\u00e9s des compagnies du portefeuille \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">05.13.2026<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">VoxCell BioInnovation et adMare BioInnovations s\u2019associent pour faire progresser le d\u00e9veloppement de nouvelles th\u00e9rapies \u00e0 base d\u2019anticorps gr\u00e2ce \u00e0 une plateforme de tissus vascularis\u00e9s repr\u00e9sentative de la physiologie humaine<\/p>\n    <\/a>\n\n<\/div><\/li><li class=\"wp-block-post post-1817 post type-post status-publish format-standard has-post-thumbnail hentry category-actualites-dadmare category-actualites-des-compagnies-du-portefeuille\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/abbvie-et-admare-bioinnovations-nomment-rime-therapeutics-laureat-du-prix-abbvie-des-innovateurs-en-biotechnologies-au-quebec\/\" title=\"AbbVie et adMare BioInnovations nomment RIME Therapeutics laur\u00e9at du Prix AbbVie des innovateurs en biotechnologies au Qu\u00e9bec\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1199\" height=\"628\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/04\/announcement-1-1777575859.png\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Actualit\u00e9s d\u2019adMare, Actualit\u00e9s des compagnies du portefeuille \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">04.30.2026<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">AbbVie et adMare BioInnovations nomment RIME Therapeutics laur\u00e9at du Prix AbbVie des innovateurs en biotechnologies au Qu\u00e9bec<\/p>\n    <\/a>\n\n<\/div><\/li><li class=\"wp-block-post post-1821 post type-post status-publish format-standard has-post-thumbnail hentry category-actualites-des-compagnies-du-portefeuille\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/epitopea-annonce-lapprobation-de-la-demande-dessai-clinique-ovact-pour-le-cryptivax-1001-dans-le-cancer-de-lovaire-sereux-de-haut-grade-avance\/\" title=\"Epitopea annonce l&#8217;approbation de la demande d&#8217;essai clinique OVACT pour le CryptiVax-1001 dans le cancer de l&#8217;ovaire s\u00e9reux de haut grade avanc\u00e9\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1200\" height=\"628\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/epitopea-news-fr-1739974973.png\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Actualit\u00e9s des compagnies du portefeuille \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">04.23.2026<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">Epitopea annonce l&#8217;approbation de la demande d&#8217;essai clinique OVACT pour le CryptiVax-1001 dans le cancer de l&#8217;ovaire s\u00e9reux de haut grade avanc\u00e9<\/p>\n    <\/a>\n\n<\/div><\/li><li class=\"wp-block-post post-1824 post type-post status-publish format-standard has-post-thumbnail hentry category-actualites-des-compagnies-du-portefeuille\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/therapeutiques-thryv-commence-ladministration-du-traitement-aux-patients-dans-le-cadre-de-letude-clinique-wave-ii-pour-le-sqtl-et-recoit-la-designation-fast-track-de-la-fda-pour-le-thrv-126\/\" title=\"Th\u00e9rapeutiques Thryv commence l&#8217;administration du traitement aux patients dans le cadre de l\u2019\u00e9tude clinique Wave II pour le SQTL et re\u00e7oit la d\u00e9signation Fast Track de la FDA pour le THRV-1268\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1199\" height=\"628\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/thryv-therapeutics-fr-1-1758136900.png\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Actualit\u00e9s des compagnies du portefeuille \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">04.22.2026<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">Th\u00e9rapeutiques Thryv commence l&#8217;administration du traitement aux patients dans le cadre de l\u2019\u00e9tude clinique Wave II pour le SQTL et re\u00e7oit la d\u00e9signation Fast Track de la FDA pour le THRV-1268<\/p>\n    <\/a>\n\n<\/div><\/li><li class=\"wp-block-post post-1498 post type-post status-publish format-standard has-post-thumbnail hentry category-actualites-dadmare\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/admare-bioinnovations-inaugure-officiellement-le-centre-dinnovation-m4-a-vancouver-pour-soutenir-la-croissance-de-compagnies-des-sciences-de-la-vie-du-canada\/\" title=\"adMare BioInnovations inaugure officiellement le Centre d\u2019innovation M4 \u00e0 Vancouver pour soutenir la croissance de compagnies des sciences de la vie du Canada\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1198\" height=\"628\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/04\/annoucement_m4_fr-1776363947.png\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Actualit\u00e9s d\u2019adMare \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">04.16.2026<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">adMare BioInnovations inaugure officiellement le Centre d\u2019innovation M4 \u00e0 Vancouver pour soutenir la croissance de compagnies des sciences de la vie du Canada<\/p>\n    <\/a>\n\n<\/div><\/li><li class=\"wp-block-post post-1827 post type-post status-publish format-standard has-post-thumbnail hentry category-actualites-des-compagnies-du-portefeuille\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/kainova-therapeutiques-etend-lessai-clinique-de-phase-i-ii-domisol-avec-le-traitement-du-premier-patient-en-europe-evaluant-dt-7012-un-anticorps-anti-ccr8-depletant-les-tregs\/\" title=\"Kainova Th\u00e9rapeutiques \u00e9tend l\u2019essai clinique de Phase I \/ II DOMISOL avec le traitement du premier patient en Europe \u00e9valuant DT-7012, un anticorps anti-CCR8 d\u00e9pl\u00e9tant les Tregs\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1198\" height=\"628\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/zymeworks-en-1768231861.png\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Actualit\u00e9s des compagnies du portefeuille \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">04.09.2026<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">Kainova Th\u00e9rapeutiques \u00e9tend l\u2019essai clinique de Phase I \/ II DOMISOL avec le traitement du premier patient en Europe \u00e9valuant DT-7012, un anticorps anti-CCR8 d\u00e9pl\u00e9tant les Tregs<\/p>\n    <\/a>\n\n<\/div><\/li><li class=\"wp-block-post post-1830 post type-post status-publish format-standard has-post-thumbnail hentry category-actualites-dadmare\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/annonce-de-la-direction-dadmare-bioinnovations\/\" title=\"Annonce de la direction d\u2019adMare BioInnovations\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1199\" height=\"628\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/03\/fr-leadership-1774897290.png\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Actualit\u00e9s d\u2019adMare \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">03.31.2026<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">Annonce de la direction d\u2019adMare BioInnovations<\/p>\n    <\/a>\n\n<\/div><\/li><li class=\"wp-block-post post-1833 post type-post status-publish format-standard has-post-thumbnail hentry category-actualites-des-compagnies-du-portefeuille\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/genome-canada-et-ontario-genomics-attribuent-une-subvention-de-18-million-de-dollars-a-specific-biologics-et-a-western-university-pour-developper-une-plateforme-dapprentissage-automatique-vi\/\" title=\"G\u00e9nome Canada et Ontario Genomics attribuent une subvention de 1,8 million de dollars \u00e0 Specific Biologics et \u00e0 Western University pour d\u00e9velopper une plateforme d\u2019apprentissage automatique visant \u00e0 acc\u00e9l\u00e9rer le d\u00e9veloppement des th\u00e9rapies de l\u2019entreprise\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1200\" height=\"628\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/specificfr-1749651003.png\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Actualit\u00e9s des compagnies du portefeuille \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">03.19.2026<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">G\u00e9nome Canada et Ontario Genomics attribuent une subvention de 1,8 million de dollars \u00e0 Specific Biologics et \u00e0 Western University pour d\u00e9velopper une plateforme d\u2019apprentissage automatique visant \u00e0 acc\u00e9l\u00e9rer le d\u00e9veloppement des th\u00e9rapies de l\u2019entreprise<\/p>\n    <\/a>\n\n<\/div><\/li><li class=\"wp-block-post post-1836 post type-post status-publish format-standard has-post-thumbnail hentry category-actualites-des-compagnies-du-portefeuille\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/kainova-therapeutiques-annonce-des-resultats-positifs-de-phase-i-pour-dt-9081-antagoniste-du-recepteur-ep4r-dans-les-tumeurs-solides-avancees\/\" title=\"Kainova Th\u00e9rapeutiques annonce des r\u00e9sultats positifs de Phase I pour DT-9081, antagoniste du r\u00e9cepteur EP4R, dans les tumeurs solides avanc\u00e9es\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1198\" height=\"628\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/zymeworks-en-1768231861-1.png\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Actualit\u00e9s des compagnies du portefeuille \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">03.10.2026<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">Kainova Th\u00e9rapeutiques annonce des r\u00e9sultats positifs de Phase I pour DT-9081, antagoniste du r\u00e9cepteur EP4R, dans les tumeurs solides avanc\u00e9es<\/p>\n    <\/a>\n\n<\/div><\/li><li class=\"wp-block-post post-1839 post type-post status-publish format-standard has-post-thumbnail hentry category-actualites-dadmare category-actualites-des-compagnies-du-portefeuille\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/26therapeutics-inc-une-nouvelle-compagnie-biotechnologique-canadienne-sattaque-a-la-cause-fondamentale-de-la-secheresse-oculaire-grace-a-une-therapie-de-premiere-classe\/\" title=\"26therapeutics Inc., une nouvelle compagnie biotechnologique canadienne s\u2019attaque \u00e0 la cause fondamentale de la s\u00e9cheresse oculaire gr\u00e2ce \u00e0 une th\u00e9rapie de premi\u00e8re classe\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1198\" height=\"628\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/03\/26tx_fr-1772591581.png\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Actualit\u00e9s d\u2019adMare, Actualit\u00e9s des compagnies du portefeuille \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">03.04.2026<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">26therapeutics Inc., une nouvelle compagnie biotechnologique canadienne s\u2019attaque \u00e0 la cause fondamentale de la s\u00e9cheresse oculaire gr\u00e2ce \u00e0 une th\u00e9rapie de premi\u00e8re classe<\/p>\n    <\/a>\n\n<\/div><\/li><li class=\"wp-block-post post-1841 post type-post status-publish format-standard has-post-thumbnail hentry category-actualites-des-compagnies-du-portefeuille\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/kainova-therapeutiques-securise-32-millions-de-cad-pour-accelerer-le-developpement-de-son-portefeuille-en-immuno-oncologie-et-inflammation\/\" title=\"Kainova Th\u00e9rapeutiques s\u00e9curise 32 millions de $CAD pour acc\u00e9l\u00e9rer le d\u00e9veloppement de son portefeuille en immuno-oncologie et inflammation.\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1198\" height=\"628\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/zymeworks-en-1768231861-1.png\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Actualit\u00e9s des compagnies du portefeuille \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">02.10.2026<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">Kainova Th\u00e9rapeutiques s\u00e9curise 32 millions de $CAD pour acc\u00e9l\u00e9rer le d\u00e9veloppement de son portefeuille en immuno-oncologie et inflammation.<\/p>\n    <\/a>\n\n<\/div><\/li><li class=\"wp-block-post post-1844 post type-post status-publish format-standard has-post-thumbnail hentry category-actualites-des-compagnies-du-portefeuille\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/ocythera-obtient-un-financement-damorcage-dadmare-bioinnovations-et-du-fonds-impulsion-pour-faire-progresser-des-therapies-contre-les-maladies-osseuses-rares\/\" title=\"Ocythera obtient un financement d\u2019amor\u00e7age d\u2019adMare BioInnovations et du Fonds Impulsion pour faire progresser des th\u00e9rapies contre les maladies osseuses rares\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1198\" height=\"628\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/01\/ocythera_fr-1769531789.png\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Actualit\u00e9s des compagnies du portefeuille \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">01.27.2026<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">Ocythera obtient un financement d\u2019amor\u00e7age d\u2019adMare BioInnovations et du Fonds Impulsion pour faire progresser des th\u00e9rapies contre les maladies osseuses rares<\/p>\n    <\/a>\n\n<\/div><\/li><li class=\"wp-block-post post-1847 post type-post status-publish format-standard has-post-thumbnail hentry category-actualites-dadmare category-actualites-des-compagnies-du-portefeuille\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/admare-bioinnovations-annonce-la-creation-docythera-une-nouvelle-compagnie-canadienne-en-sciences-de-la-vie-qui-fait-progresser-les-therapies-pour-les-maladies-osseuses-rares\/\" title=\"adMare BioInnovations annonce la cr\u00e9ation d\u2019Ocythera: une nouvelle compagnie canadienne en sciences de la vie qui fait progresser les th\u00e9rapies pour les maladies osseuses rares\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1198\" height=\"628\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/01\/annonce_ocythera-1768345460.png\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Actualit\u00e9s d\u2019adMare, Actualit\u00e9s des compagnies du portefeuille \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">01.15.2026<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">adMare BioInnovations annonce la cr\u00e9ation d\u2019Ocythera: une nouvelle compagnie canadienne en sciences de la vie qui fait progresser les th\u00e9rapies pour les maladies osseuses rares<\/p>\n    <\/a>\n\n<\/div><\/li><li class=\"wp-block-post post-1849 post type-post status-publish format-standard has-post-thumbnail hentry category-actualites-des-compagnies-du-portefeuille\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/therapeutiques-thryv-lance-wave-ii-une-etude-pivotale-de-phase-2-3-sur-le-syndrome-du-qt-long-de-type-2\/\" title=\"Th\u00e9rapeutiques Thryv lance Wave II, une \u00e9tude pivotale de phase 2\/3 sur le syndrome du QT long de type 2\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1199\" height=\"628\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/thryv-therapeutics-fr-1-1758136900.png\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Actualit\u00e9s des compagnies du portefeuille \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">01.13.2026<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">Th\u00e9rapeutiques Thryv lance Wave II, une \u00e9tude pivotale de phase 2\/3 sur le syndrome du QT long de type 2<\/p>\n    <\/a>\n\n<\/div><\/li><li class=\"wp-block-post post-1851 post type-post status-publish format-standard has-post-thumbnail hentry category-actualites-des-compagnies-du-portefeuille\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/domain-therapeutics-devient-kainova-therapeutiques-et-fait-progresser-son-pipeline-clinique-de-therapies-modulatrices-rcpg\/\" title=\"Domain Therapeutics devient Kainova Th\u00e9rapeutiques et fait progresser son pipeline clinique de th\u00e9rapies modulatrices RCPG\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1198\" height=\"628\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/zymeworks-en-1768231861-1.png\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Actualit\u00e9s des compagnies du portefeuille \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">01.12.2026<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">Domain Therapeutics devient Kainova Th\u00e9rapeutiques et fait progresser son pipeline clinique de th\u00e9rapies modulatrices RCPG<\/p>\n    <\/a>\n\n<\/div><\/li><li class=\"wp-block-post post-1854 post type-post status-publish format-standard has-post-thumbnail hentry category-actualites-des-compagnies-du-portefeuille\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/find-therapeutics-annonce-une-extension-de-son-financement-de-serie-a-et-la-nomination-du-dr-thierry-abribat-a-la-presidence-executive-de-son-conseil-dadministration\/\" title=\"Find Therapeutics annonce une extension de son financement de s\u00e9rie A et la nomination du Dr Thierry Abribat \u00e0 la pr\u00e9sidence ex\u00e9cutive de son conseil d\u2019administration\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1199\" height=\"628\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/find-therapeutics-fr-1744304415.png\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Actualit\u00e9s des compagnies du portefeuille \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">01.09.2026<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">Find Therapeutics annonce une extension de son financement de s\u00e9rie A et la nomination du Dr Thierry Abribat \u00e0 la pr\u00e9sidence ex\u00e9cutive de son conseil d\u2019administration<\/p>\n    <\/a>\n\n<\/div><\/li><li class=\"wp-block-post post-1856 post type-post status-publish format-standard has-post-thumbnail hentry category-actualites-des-compagnies-du-portefeuille\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/therapeutiques-thryv-annonce-des-resultats-positifs-de-letude-de-phase-1-du-thrv-1268-chez-des-participants-obeses\/\" title=\"Th\u00e9rapeutiques Thryv annonce des r\u00e9sultats positifs de l\u2019\u00e9tude de phase 1 du THRV-1268 chez des participants ob\u00e8ses\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1199\" height=\"628\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/thryv-therapeutics-fr-1-1758136900.png\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Actualit\u00e9s des compagnies du portefeuille \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">12.17.2025<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">Th\u00e9rapeutiques Thryv annonce des r\u00e9sultats positifs de l\u2019\u00e9tude de phase 1 du THRV-1268 chez des participants ob\u00e8ses<\/p>\n    <\/a>\n\n<\/div><\/li><li class=\"wp-block-post post-1858 post type-post status-publish format-standard has-post-thumbnail hentry category-actualites-des-compagnies-du-portefeuille\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/specific-biologics-accueille-le-leader-chevronne-en-biotechnologie-le-dr-richard-glickman-au-sein-de-son-conseil-dadministration\/\" title=\"Specific Biologics accueille le leader chevronn\u00e9 en biotechnologie, le Dr Richard Glickman, au sein de son conseil d\u2019administration\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1200\" height=\"628\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/specificfr-1749651003.png\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Actualit\u00e9s des compagnies du portefeuille \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">12.16.2025<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">Specific Biologics accueille le leader chevronn\u00e9 en biotechnologie, le Dr Richard Glickman, au sein de son conseil d\u2019administration<\/p>\n    <\/a>\n\n<\/div><\/li><li class=\"wp-block-post post-1861 post type-post status-publish format-standard has-post-thumbnail hentry category-actualites-dadmare\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/admare-bioinnovations-lance-la-cohorte-viii-de-linstitut-pour-cadres-superieurs-visant-a-renforcer-le-leadership-propulsant-la-croissance-des-compagnies-canadiennes-en-sciences-de-la-vie\/\" title=\"adMare BioInnovations lance la Cohorte VIII de l\u2019Institut pour cadres sup\u00e9rieurs visant \u00e0 renforcer le leadership propulsant la croissance des compagnies canadiennes en sciences de la vie\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1198\" height=\"628\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2025\/12\/ei_cohort-viii_fr-1765477633.png\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Actualit\u00e9s d\u2019adMare \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">12.11.2025<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">adMare BioInnovations lance la Cohorte VIII de l\u2019Institut pour cadres sup\u00e9rieurs visant \u00e0 renforcer le leadership propulsant la croissance des compagnies canadiennes en sciences de la vie<\/p>\n    <\/a>\n\n<\/div><\/li><li class=\"wp-block-post post-1864 post type-post status-publish format-standard has-post-thumbnail hentry category-actualites-des-compagnies-du-portefeuille\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/therapeutiques-thryv-renforce-son-equipe-de-direction-avec-la-nomination-de-matt-killeen-phd-au-poste-de-directeur-des-affaires-commerciales-chief-business-officer\/\" title=\"Th\u00e9rapeutiques Thryv renforce son \u00e9quipe de direction avec la nomination de Matt Killeen, PhD, au poste de directeur des affaires commerciales (Chief Business Officer)\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1199\" height=\"628\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/thryv-therapeutics-fr-1-1758136900.png\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Actualit\u00e9s des compagnies du portefeuille \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">12.03.2025<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">Th\u00e9rapeutiques Thryv renforce son \u00e9quipe de direction avec la nomination de Matt Killeen, PhD, au poste de directeur des affaires commerciales (Chief Business Officer)<\/p>\n    <\/a>\n\n<\/div><\/li><li class=\"wp-block-post post-1867 post type-post status-publish format-standard has-post-thumbnail hentry category-actualites-dadmare\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/castl-elargit-la-formation-nationale-en-biofabrication-avec-le-programme-bioinnovation-scientist-bis\/\" title=\"CASTL \u00e9largit la formation nationale en biofabrication avec le programme BioInnovation Scientist (BIS)\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1840\" height=\"1021\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/bis-image-1763743515-1764303858.png\" class=\"attachment-full size-full wp-post-image\" alt=\"\" srcset=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/bis-image-1763743515-1764303858.png 1840w, https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/bis-image-1763743515-1764303858-1536x852.png 1536w\" sizes=\"auto, (max-width: 1840px) 100vw, 1840px\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Actualit\u00e9s d\u2019adMare \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">11.27.2025<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">CASTL \u00e9largit la formation nationale en biofabrication avec le programme BioInnovation Scientist (BIS)<\/p>\n    <\/a>\n\n<\/div><\/li><li class=\"wp-block-post post-1870 post type-post status-publish format-standard has-post-thumbnail hentry category-actualites-dadmare\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/lancement-du-prix-abbvie-des-innovateurs-en-biotechnologies-au-quebec-abbvie-et-admare-bioinnovations-encouragent-linnovation-dans-le-domaine-des-sciences-de-la-vie\/\" title=\"Lancement du Prix AbbVie des innovateurs en biotechnologies au Qu\u00e9bec : AbbVie et adMare BioInnovations encouragent l\u2019innovation dans le domaine des sciences de la vie\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1200\" height=\"628\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/announcement-1-1763995590.png\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Actualit\u00e9s d\u2019adMare \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">11.25.2025<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">Lancement du Prix AbbVie des innovateurs en biotechnologies au Qu\u00e9bec : AbbVie et adMare BioInnovations encouragent l\u2019innovation dans le domaine des sciences de la vie<\/p>\n    <\/a>\n\n<\/div><\/li><li class=\"wp-block-post post-1874 post type-post status-publish format-standard has-post-thumbnail hentry category-actualites-des-compagnies-du-portefeuille\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/pathway-to-cures-investit-dans-seragene-therapeutics\/\" title=\"Pathway to Cures investit dans SeraGene Therapeutics\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1198\" height=\"628\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/accelmay2024en-1763649153.png\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Actualit\u00e9s des compagnies du portefeuille \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">11.20.2025<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">Pathway to Cures investit dans SeraGene Therapeutics<\/p>\n    <\/a>\n\n<\/div><\/li><li class=\"wp-block-post post-1877 post type-post status-publish format-standard has-post-thumbnail hentry category-actualites-des-compagnies-du-portefeuille\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/amy-rudolph-phd-rejoint-le-conseil-dadministration-de-therapeutiques-thryv-inc-pour-soutenir-la-progression-du-portefeuille-vers-linsuffisance-cardiaque\/\" title=\"Amy Rudolph, PhD, rejoint le conseil d\u2019administration de Th\u00e9rapeutiques Thryv Inc. pour soutenir la progression du portefeuille vers l\u2019insuffisance cardiaque\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1199\" height=\"628\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/thryv-therapeutics-fr-1-1758136900.png\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Actualit\u00e9s des compagnies du portefeuille \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">11.19.2025<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">Amy Rudolph, PhD, rejoint le conseil d\u2019administration de Th\u00e9rapeutiques Thryv Inc. pour soutenir la progression du portefeuille vers l\u2019insuffisance cardiaque<\/p>\n    <\/a>\n\n<\/div><\/li><li class=\"wp-block-post post-1881 post type-post status-publish format-standard has-post-thumbnail hentry category-perspectives-dadmare\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/alors-que-les-etats-unis-vacillent-le-quebec-doit-tenir-bon-en-sciences-de-la-vie\/\" title=\"Alors que les \u00c9tats-Unis vacillent, le Qu\u00e9bec doit tenir bon en sciences de la vie\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"923\" height=\"616\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/d2d689d995f73d6583f6ef266bf80233-1762383436.webp\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Perspectives d&#039;adMare \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">11.05.2025<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">Alors que les \u00c9tats-Unis vacillent, le Qu\u00e9bec doit tenir bon en sciences de la vie<\/p>\n    <\/a>\n\n<\/div><\/li><li class=\"wp-block-post post-1885 post type-post status-publish format-standard has-post-thumbnail hentry category-actualites-des-compagnies-du-portefeuille\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/domain-therapeutics-administre-les-premieres-doses-aux-patients-dans-un-essai-de-phase-i-ii-de-dt-7012-ciblant-ccr8-dans-les-tumeurs-solides\/\" title=\"Domain Therapeutics administre les premi\u00e8res doses aux patients dans un essai de phase I \/ II de DT-7012 ciblant CCR8 dans les tumeurs solides\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1200\" height=\"628\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/domain-tx-fr-1686256265.png\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Actualit\u00e9s des compagnies du portefeuille \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">10.28.2025<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">Domain Therapeutics administre les premi\u00e8res doses aux patients dans un essai de phase I \/ II de DT-7012 ciblant CCR8 dans les tumeurs solides<\/p>\n    <\/a>\n\n<\/div><\/li><li class=\"wp-block-post post-1888 post type-post status-publish format-standard has-post-thumbnail hentry category-actualites-des-compagnies-du-portefeuille\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/epitopea-renforce-son-comite-consultatif-scientifique-avec-la-nomination-de-quatre-experts-de-renommee-mondiale-en-immunologie-et-immunotherapie-du-cancer\/\" title=\"Epitopea renforce son comit\u00e9 consultatif scientifique avec la nomination de quatre experts de renomm\u00e9e mondiale en immunologie et immunoth\u00e9rapie du cancer\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1200\" height=\"628\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/epitopea-news-fr-1739974973.png\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Actualit\u00e9s des compagnies du portefeuille \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">09.18.2025<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">Epitopea renforce son comit\u00e9 consultatif scientifique avec la nomination de quatre experts de renomm\u00e9e mondiale en immunologie et immunoth\u00e9rapie du cancer<\/p>\n    <\/a>\n\n<\/div><\/li><li class=\"wp-block-post post-1894 post type-post status-publish format-standard has-post-thumbnail hentry category-actualites-des-compagnies-du-portefeuille\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/abdera-therapeutics-presente-les-premieres-donnees-cliniques-de-phase-1-sur-labd-147-une-therapie-radiopharmaceutique-de-nouvelle-generation-ciblant-dll3-lors-du-congres-mondial-2025-de-l\/\" title=\"Abdera Therapeutics pr\u00e9sente les premi\u00e8res donn\u00e9es cliniques de phase 1 sur l\u2019ABD-147, une th\u00e9rapie radiopharmaceutique de nouvelle g\u00e9n\u00e9ration ciblant DLL3, lors du congr\u00e8s mondial 2025 de l\u2019IASLC sur le cancer du poumon.\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1199\" height=\"628\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/abdera-therapeutics-fr-1757440786.png\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Actualit\u00e9s des compagnies du portefeuille \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">09.17.2025<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">Abdera Therapeutics pr\u00e9sente les premi\u00e8res donn\u00e9es cliniques de phase 1 sur l\u2019ABD-147, une th\u00e9rapie radiopharmaceutique de nouvelle g\u00e9n\u00e9ration ciblant DLL3, lors du congr\u00e8s mondial 2025 de l\u2019IASLC sur le cancer du poumon.<\/p>\n    <\/a>\n\n<\/div><\/li><li class=\"wp-block-post post-1891 post type-post status-publish format-standard has-post-thumbnail hentry category-actualites-des-compagnies-du-portefeuille\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/therapeutiques-thryv-annonce-lautorisation-ind-par-la-fda-pour-thrv-1268-dans-le-syndrome-du-qt-long\/\" title=\"Th\u00e9rapeutiques Thryv annonce l\u2019autorisation IND par la FDA pour THRV-1268 dans le Syndrome du QT Long\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1199\" height=\"628\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/thryv-therapeutics-fr-1-1758136900.png\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Actualit\u00e9s des compagnies du portefeuille \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">09.17.2025<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">Th\u00e9rapeutiques Thryv annonce l\u2019autorisation IND par la FDA pour THRV-1268 dans le Syndrome du QT Long<\/p>\n    <\/a>\n\n<\/div><\/li><li class=\"wp-block-post post-1897 post type-post status-publish format-standard has-post-thumbnail hentry category-actualites-des-compagnies-du-portefeuille\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/thryv-therapeutiques-recoit-lautorisation-ind-de-la-fda-pour-thrv-1268-dans-linsuffisance-cardiaque-et-la-fibrillation-auriculaire-et-presente-des-resultats-sgk1-et-jardiance-au-cong\/\" title=\"Thryv Th\u00e9rapeutiques re\u00e7oit l\u2019autorisation IND de la FDA pour THRV-1268 dans l\u2019insuffisance cardiaque et la fibrillation auriculaire et pr\u00e9sente des r\u00e9sultats SGK1 et Jardiance au congr\u00e8s ESC 2025\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1199\" height=\"628\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/thryv-therapeutics-fr-1-1758136900.png\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Actualit\u00e9s des compagnies du portefeuille \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">09.08.2025<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">Thryv Th\u00e9rapeutiques re\u00e7oit l\u2019autorisation IND de la FDA pour THRV-1268 dans l\u2019insuffisance cardiaque et la fibrillation auriculaire et pr\u00e9sente des r\u00e9sultats SGK1 et Jardiance au congr\u00e8s ESC 2025<\/p>\n    <\/a>\n\n<\/div><\/li><li class=\"wp-block-post post-1900 post type-post status-publish format-standard has-post-thumbnail hentry category-actualites-dadmare\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/linstitut-pour-cadres-superieurs-dadmare-ouvre-les-candidatures-pour-sa-huitieme-cohorte\/\" title=\"L\u2019Institut pour cadres sup\u00e9rieurs d\u2019adMare ouvre les candidatures pour sa huiti\u00e8me cohorte\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1199\" height=\"628\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/exec-institute-cohort-viii-announcement-1-1753713106.png\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Actualit\u00e9s d\u2019adMare \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">07.28.2025<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">L\u2019Institut pour cadres sup\u00e9rieurs d\u2019adMare ouvre les candidatures pour sa huiti\u00e8me cohorte<\/p>\n    <\/a>\n\n<\/div><\/li><li class=\"wp-block-post post-1903 post type-post status-publish format-standard has-post-thumbnail hentry category-actualites-des-compagnies-du-portefeuille\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/epitopea-renforce-ses-capacites-de-recherche-et-de-developpement-clinique-pour-accelerer-le-passage-a-la-clinique\/\" title=\"Epitopea renforce ses capacit\u00e9s de recherche et de d\u00e9veloppement clinique pour acc\u00e9l\u00e9rer le passage \u00e0 la clinique\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1200\" height=\"628\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/epitopea-news-fr-1739974973.png\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Actualit\u00e9s des compagnies du portefeuille \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">07.10.2025<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">Epitopea renforce ses capacit\u00e9s de recherche et de d\u00e9veloppement clinique pour acc\u00e9l\u00e9rer le passage \u00e0 la clinique<\/p>\n    <\/a>\n\n<\/div><\/li><li class=\"wp-block-post post-1906 post type-post status-publish format-standard has-post-thumbnail hentry category-perspectives-dadmare\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/un-nouveau-rapport-de-linstitut-admare-examine-les-flux-de-capitaux-dans-le-secteur-canadien-des-sciences-de-la-vie-et-lurgence-de-mieux-capter-la-valeur-economique-au-pays\/\" title=\"Un nouveau rapport de l\u2019Institut adMare examine les flux de capitaux dans le secteur canadien des sciences de la vie et l&#8217;urgence de mieux capter la valeur \u00e9conomique au pays\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1197\" height=\"627\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/heading-1752065028.png\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Perspectives d&#039;adMare \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">07.09.2025<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">Un nouveau rapport de l\u2019Institut adMare examine les flux de capitaux dans le secteur canadien des sciences de la vie et l&#8217;urgence de mieux capter la valeur \u00e9conomique au pays<\/p>\n    <\/a>\n\n<\/div><\/li><li class=\"wp-block-post post-1910 post type-post status-publish format-standard has-post-thumbnail hentry category-actualites-des-compagnies-du-portefeuille\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/9bio-therapeutiques-selectionnee-par-le-merck-global-health-innovation-fund-et-le-cqdm-pour-un-investissement-strategique-et-un-programme-dacceleration\/\" title=\"9Bio Th\u00e9rapeutiques s\u00e9lectionn\u00e9e par le Merck Global Health Innovation Fund et le CQDM pour un investissement strat\u00e9gique et un programme d\u2019acc\u00e9l\u00e9ration\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1200\" height=\"628\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/accelmay2024en-2-1740158128.png\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Actualit\u00e9s des compagnies du portefeuille \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">06.23.2025<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">9Bio Th\u00e9rapeutiques s\u00e9lectionn\u00e9e par le Merck Global Health Innovation Fund et le CQDM pour un investissement strat\u00e9gique et un programme d\u2019acc\u00e9l\u00e9ration<\/p>\n    <\/a>\n\n<\/div><\/li><li class=\"wp-block-post post-1913 post type-post status-publish format-standard has-post-thumbnail hentry category-actualites-des-compagnies-du-portefeuille\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/specific-biologics-accueille-paul-j-hastings-a-titre-de-president-du-conseil-dadministration\/\" title=\"Specific Biologics accueille Paul J. Hastings \u00e0 titre de pr\u00e9sident du conseil d\u2019administration\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1200\" height=\"628\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/specificfr-1749651003.png\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Actualit\u00e9s des compagnies du portefeuille \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">06.11.2025<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">Specific Biologics accueille Paul J. Hastings \u00e0 titre de pr\u00e9sident du conseil d\u2019administration<\/p>\n    <\/a>\n\n<\/div><\/li><li class=\"wp-block-post post-1918 post type-post status-publish format-standard has-post-thumbnail hentry category-actualites-des-compagnies-du-portefeuille\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/une-collaboration-appuyee-par-le-quebec-a-hauteur-de-18-m-entre-9bio-et-vega-fait-progresser-linnovation-en-oncologie-de-precision\/\" title=\"Une collaboration appuy\u00e9e par le Qu\u00e9bec \u00e0 hauteur de 1,8 M$ entre 9Bio et Vega fait progresser l\u2019innovation en oncologie de pr\u00e9cision\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1200\" height=\"628\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2025\/06\/accelmay2024en-2-1740158243.png\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Actualit\u00e9s des compagnies du portefeuille \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">05.14.2025<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">Une collaboration appuy\u00e9e par le Qu\u00e9bec \u00e0 hauteur de 1,8 M$ entre 9Bio et Vega fait progresser l\u2019innovation en oncologie de pr\u00e9cision<\/p>\n    <\/a>\n\n<\/div><\/li><li class=\"wp-block-post post-1921 post type-post status-publish format-standard has-post-thumbnail hentry category-actualites-des-compagnies-du-portefeuille\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/zucara-therapeutics-annonce-une-deuxieme-et-derniere-cloture-de-son-financement-de-serie-b-totalisant-25-millions-us\/\" title=\"Zucara Therapeutics annonce une deuxi\u00e8me et derni\u00e8re cl\u00f4ture de son financement de s\u00e9rie B totalisant 25 millions $\u202fUS\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1199\" height=\"628\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/zucaranews-fr-1746106189.png\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Actualit\u00e9s des compagnies du portefeuille \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">05.01.2025<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">Zucara Therapeutics annonce une deuxi\u00e8me et derni\u00e8re cl\u00f4ture de son financement de s\u00e9rie B totalisant 25 millions $\u202fUS<\/p>\n    <\/a>\n\n<\/div><\/li><li class=\"wp-block-post post-1924 post type-post status-publish format-standard has-post-thumbnail hentry category-actualites-des-compagnies-du-portefeuille\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/deux-expertises-cles-pour-accelerer-le-developpement-de-ftx-101\/\" title=\"Deux expertises cl\u00e9s pour acc\u00e9l\u00e9rer le d\u00e9veloppement de FTX-101\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1199\" height=\"628\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/find-therapeutics-fr-1744304415.png\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Actualit\u00e9s des compagnies du portefeuille \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">04.10.2025<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">Deux expertises cl\u00e9s pour acc\u00e9l\u00e9rer le d\u00e9veloppement de FTX-101<\/p>\n    <\/a>\n\n<\/div><\/li><li class=\"wp-block-post post-1927 post type-post status-publish format-standard has-post-thumbnail hentry category-actualites-des-compagnies-du-portefeuille\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/9bio-therapeutiques-obtient-un-financement-strategique-pour-faire-progresser-son-pipeline-en-oncologie\/\" title=\"9Bio Th\u00e9rapeutiques obtient un financement strat\u00e9gique pour faire progresser son pipeline en oncologie\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1200\" height=\"628\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/accelmay2024en-2-1740158128.png\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Actualit\u00e9s des compagnies du portefeuille \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">02.21.2025<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">9Bio Th\u00e9rapeutiques obtient un financement strat\u00e9gique pour faire progresser son pipeline en oncologie<\/p>\n    <\/a>\n\n<\/div><\/li><li class=\"wp-block-post post-1929 post type-post status-publish format-standard has-post-thumbnail hentry category-actualites-des-compagnies-du-portefeuille\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/epitopea-annonce-un-accord-de-licence-et-de-collaboration-en-recherche-avec-msd-pour-identifier-les-antigenes-tumoraux-specifiques-cryptigenmc\/\" title=\"Epitopea annonce un accord de licence et de collaboration en recherche avec MSD pour identifier les antig\u00e8nes tumoraux sp\u00e9cifiques CryptigenMC\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1200\" height=\"628\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/epitopea-news-fr-1739974973.png\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Actualit\u00e9s des compagnies du portefeuille \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">02.19.2025<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">Epitopea annonce un accord de licence et de collaboration en recherche avec MSD pour identifier les antig\u00e8nes tumoraux sp\u00e9cifiques CryptigenMC<\/p>\n    <\/a>\n\n<\/div><\/li><li class=\"wp-block-post post-1916 post type-post status-publish format-standard has-post-thumbnail hentry category-actualites-des-compagnies-du-portefeuille\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/epitopea-annonce-un-article-dans-nature-cancer-sur-de-nouvelles-cibles-dimmunotherapie-dans-le-melanome-et-le-cancer-du-poumon-non-a-petites-cellules-nsclc\/\" title=\"Epitopea annonce un article dans Nature Cancer sur de nouvelles cibles d&#8217;immunoth\u00e9rapie dans le m\u00e9lanome et le cancer du poumon non \u00e0 petites cellules (NSCLC)\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1200\" height=\"628\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/epitopea-news-fr-1739974973.png\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Actualit\u00e9s des compagnies du portefeuille \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">02.19.2025<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">Epitopea annonce un article dans Nature Cancer sur de nouvelles cibles d&#8217;immunoth\u00e9rapie dans le m\u00e9lanome et le cancer du poumon non \u00e0 petites cellules (NSCLC)<\/p>\n    <\/a>\n\n<\/div><\/li><li class=\"wp-block-post post-1932 post type-post status-publish format-standard has-post-thumbnail hentry category-actualites-dadmare\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/le-gouvernement-du-canada-investit-6-millions-de-dollars-pour-stimuler-la-croissance-du-secteur-des-sciences-de-la-vie-en-colombie-britannique\/\" title=\"Le gouvernement du Canada investit 6 millions de dollars pour stimuler la croissance du secteur des sciences de la vie en Colombie-Britannique\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1198\" height=\"628\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/annonce-1738953429.png\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Actualit\u00e9s d\u2019adMare \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">02.07.2025<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">Le gouvernement du Canada investit 6 millions de dollars pour stimuler la croissance du secteur des sciences de la vie en Colombie-Britannique<\/p>\n    <\/a>\n\n<\/div><\/li><li class=\"wp-block-post post-1936 post type-post status-publish format-standard has-post-thumbnail hentry category-actualites-dadmare\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/faits-saillants-2024-dadmare-bioinnovations\/\" title=\"Faits saillants 2024 d&#8217;adMare BioInnovations\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1198\" height=\"629\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/5_cie_fr-1734623920.png\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Actualit\u00e9s d\u2019adMare \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">12.19.2024<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">Faits saillants 2024 d&#8217;adMare BioInnovations<\/p>\n    <\/a>\n\n<\/div><\/li><li class=\"wp-block-post post-1940 post type-post status-publish format-standard has-post-thumbnail hentry category-actualites-dadmare\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/admare-bioinnovations-accueille-la-cohorte-vii-de-linstitut-pour-cadres-superieurs-renforcant-ainsi-le-leadership-du-canada-dans-le-domaine-des-sciences-de-la-vie\/\" title=\"adMare BioInnovations accueille la cohorte VII de l\u2019Institut pour cadres sup\u00e9rieurs, renfor\u00e7ant ainsi le leadership du Canada dans le domaine des sciences de la vie\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1198\" height=\"628\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/announcement-3-1-1733349885.png\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Actualit\u00e9s d\u2019adMare \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">12.04.2024<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">adMare BioInnovations accueille la cohorte VII de l\u2019Institut pour cadres sup\u00e9rieurs, renfor\u00e7ant ainsi le leadership du Canada dans le domaine des sciences de la vie<\/p>\n    <\/a>\n\n<\/div><\/li><li class=\"wp-block-post post-1944 post type-post status-publish format-standard has-post-thumbnail hentry category-actualites-des-compagnies-du-portefeuille\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/kisoji-biotechnology-recueille-41-millions-de-dollars-pour-faire-avancer-son-programme-principal-dans-les-etudes-cliniques-et-deployer-des-outils-dia-dans-les-indications-cles-du-pipeline\/\" title=\"KisoJi Biotechnology recueille 41 millions de dollars pour faire avancer son programme principal dans les \u00e9tudes cliniques et d\u00e9ployer des outils d\u2019IA dans les indications cl\u00e9s du pipeline\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1198\" height=\"628\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/kisoji-news-fr-1733150499.png\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Actualit\u00e9s des compagnies du portefeuille \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">12.02.2024<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">KisoJi Biotechnology recueille 41 millions de dollars pour faire avancer son programme principal dans les \u00e9tudes cliniques et d\u00e9ployer des outils d\u2019IA dans les indications cl\u00e9s du pipeline<\/p>\n    <\/a>\n\n<\/div><\/li><li class=\"wp-block-post post-1948 post type-post status-publish format-standard has-post-thumbnail hentry category-actualites-dadmare category-actualites-des-compagnies-du-portefeuille\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/admare-bioinnovations-transfere-son-departement-de-services-analytiques-a-paraza-pharma-stimulant-ainsi-la-croissance-et-linnovation\/\" title=\"adMare BioInnovations transf\u00e8re son d\u00e9partement de services analytiques \u00e0 Paraza Pharma, stimulant ainsi la croissance et l\u2019innovation\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1198\" height=\"628\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/paraza-fr-1732803378.png\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Actualit\u00e9s d\u2019adMare, Actualit\u00e9s des compagnies du portefeuille \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">11.28.2024<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">adMare BioInnovations transf\u00e8re son d\u00e9partement de services analytiques \u00e0 Paraza Pharma, stimulant ainsi la croissance et l\u2019innovation<\/p>\n    <\/a>\n\n<\/div><\/li><li class=\"wp-block-post post-1952 post type-post status-publish format-standard has-post-thumbnail hentry category-actualites-des-compagnies-du-portefeuille\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/la-fda-approuve-ziihera-zanidatamab-hrii-pour-le-traitement-des-adultes-atteints-dun-cancer-des-voies-biliaires-her2-positif-ihc-3-non-resecable-ou-metastatique-deja-traite\/\" title=\"La FDA approuve Ziihera\u00ae (zanidatamab-hrii) pour le traitement des adultes atteints d&#8217;un cancer des voies biliaires HER2-positif (IHC 3+), non r\u00e9s\u00e9cable ou m\u00e9tastatique, d\u00e9j\u00e0 trait\u00e9.\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1200\" height=\"628\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/zymeworks-news-fr-1729863330.png\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Actualit\u00e9s des compagnies du portefeuille \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">11.21.2024<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">La FDA approuve Ziihera\u00ae (zanidatamab-hrii) pour le traitement des adultes atteints d&#8217;un cancer des voies biliaires HER2-positif (IHC 3+), non r\u00e9s\u00e9cable ou m\u00e9tastatique, d\u00e9j\u00e0 trait\u00e9.<\/p>\n    <\/a>\n\n<\/div><\/li><li class=\"wp-block-post post-1955 post type-post status-publish format-standard has-post-thumbnail hentry category-actualites-des-compagnies-du-portefeuille\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/thryv-annonce-lachevement-du-dosage-dans-letude-phase-1-de-son-2e-nouvel-inhibiteur-de-sgk1-thrv-1268-les-etudes-sur-linsuffisance-cardiaque-et-la-fibrillation-auriculaire-debuteront-e\/\" title=\"Thryv annonce l\u2019ach\u00e8vement du dosage dans l&#8217;\u00e9tude phase 1 de son 2e nouvel inhibiteur de SGK1, THRV-1268 &#8211; Les \u00e9tudes sur l&#8217;insuffisance cardiaque et la fibrillation auriculaire d\u00e9buteront en 2025\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1199\" height=\"628\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/thryv-therapeutics-fr-1-1758136900.png\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Actualit\u00e9s des compagnies du portefeuille \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">11.15.2024<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">Thryv annonce l\u2019ach\u00e8vement du dosage dans l&#8217;\u00e9tude phase 1 de son 2e nouvel inhibiteur de SGK1, THRV-1268 &#8211; Les \u00e9tudes sur l&#8217;insuffisance cardiaque et la fibrillation auriculaire d\u00e9buteront en 2025<\/p>\n    <\/a>\n\n<\/div><\/li><li class=\"wp-block-post post-1957 post type-post status-publish format-standard has-post-thumbnail hentry category-actualites-des-compagnies-du-portefeuille\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/zucara-therapeutics-annonce-un-investissement-strategique-de-sanofi-dans-le-cadre-dun-financement-de-serie-b-de-20-millions-de-dollars-us\/\" title=\"Zucara Therapeutics annonce un investissement strat\u00e9gique de Sanofi dans le cadre d&#8217;un financement de s\u00e9rie B de 20 millions de dollars US\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1199\" height=\"628\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/zucaranews-fr-1746106189.png\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Actualit\u00e9s des compagnies du portefeuille \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">11.12.2024<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">Zucara Therapeutics annonce un investissement strat\u00e9gique de Sanofi dans le cadre d&#8217;un financement de s\u00e9rie B de 20 millions de dollars US<\/p>\n    <\/a>\n\n<\/div><\/li><li class=\"wp-block-post post-1959 post type-post status-publish format-standard has-post-thumbnail hentry category-actualites-des-compagnies-du-portefeuille\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/zymeworks-announces-first-patient-dosed-in-phase-1-clinical-trial-evaluating-zw171-in-advanced-mesothelin-expressing-cancers\/\" title=\"Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1200\" height=\"628\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/zymeworks-news-fr-1729863330.png\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Actualit\u00e9s des compagnies du portefeuille \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">10.25.2024<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers<\/p>\n    <\/a>\n\n<\/div><\/li><li class=\"wp-block-post post-1963 post type-post status-publish format-standard has-post-thumbnail hentry category-actualites-des-compagnies-du-portefeuille\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/epitopea-conclut-des-ententes-de-financement-prealable-a-la-serie-a-dun-montant-de-31-millions-de-dollars-us\/\" title=\"Epitopea conclut des ententes de financement pr\u00e9alable \u00e0 la s\u00e9rie A d\u2019un montant de 31 millions de dollars US\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1200\" height=\"628\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/epitopea-news-fr-1739974973.png\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Actualit\u00e9s des compagnies du portefeuille \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">10.24.2024<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">Epitopea conclut des ententes de financement pr\u00e9alable \u00e0 la s\u00e9rie A d\u2019un montant de 31 millions de dollars US<\/p>\n    <\/a>\n\n<\/div><\/li><li class=\"wp-block-post post-1961 post type-post status-publish format-standard has-post-thumbnail hentry category-actualites-des-compagnies-du-portefeuille\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/cancer-research-uk-et-kisoji-biotechnology-collaborent-pour-faire-avancer-le-premier-anticorps-nu-ciblant-trop2-en-clinique\/\" title=\"Cancer Research UK et KisoJi Biotechnology collaborent pour faire avancer le premier anticorps nu ciblant TROP2 en clinique\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1198\" height=\"628\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/kisoji-news-fr-1733150499.png\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Actualit\u00e9s des compagnies du portefeuille \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">10.24.2024<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">Cancer Research UK et KisoJi Biotechnology collaborent pour faire avancer le premier anticorps nu ciblant TROP2 en clinique<\/p>\n    <\/a>\n\n<\/div><\/li><li class=\"wp-block-post post-1966 post type-post status-publish format-standard has-post-thumbnail hentry category-actualites-dadmare\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/admare-bioinnovations-salue-les-succes-des-compagnies-de-laccelerateur-national-tx-admare-et-termine-son-partenariat-en-ontario-avec-mars\/\" title=\"adMare BioInnovations salue les succ\u00e8s des compagnies de l\u2019Acc\u00e9l\u00e9rateur national Tx adMare et termine son partenariat en Ontario avec MaRS\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1199\" height=\"628\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/accelannouncfr-1729602403.png\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Actualit\u00e9s d\u2019adMare \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">10.22.2024<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">adMare BioInnovations salue les succ\u00e8s des compagnies de l\u2019Acc\u00e9l\u00e9rateur national Tx adMare et termine son partenariat en Ontario avec MaRS<\/p>\n    <\/a>\n\n<\/div><\/li><li class=\"wp-block-post post-1969 post type-post status-publish format-standard has-post-thumbnail hentry category-actualites-des-compagnies-du-portefeuille\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/premier-sujet-traite-dans-le-cadre-de-letude-clinique-de-phase-1-du-ftx-101\/\" title=\"Premier sujet trait\u00e9 dans le cadre de l\u2019\u00e9tude clinique de phase 1 du FTX-101\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1199\" height=\"628\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/find-therapeutics-fr-1744304415.png\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Actualit\u00e9s des compagnies du portefeuille \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">10.21.2024<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">Premier sujet trait\u00e9 dans le cadre de l\u2019\u00e9tude clinique de phase 1 du FTX-101<\/p>\n    <\/a>\n\n<\/div><\/li><li class=\"wp-block-post post-1971 post type-post status-publish format-standard has-post-thumbnail hentry category-actualites-des-compagnies-du-portefeuille\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/thryv-therapeutics-receives-positive-top-line-results-from-wave-i-part-2-clinical-study-in-long-qt-syndrome-type-2-and-type-3-patients\/\" title=\"Thryv Therapeutics Receives Positive Top-Line Results from Wave I Part 2 Clinical Study in Long QT Syndrome Type 2 and Type 3 Patients\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1199\" height=\"628\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/thryv-therapeutics-fr-1-1758136900.png\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Actualit\u00e9s des compagnies du portefeuille \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">10.15.2024<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">Thryv Therapeutics Receives Positive Top-Line Results from Wave I Part 2 Clinical Study in Long QT Syndrome Type 2 and Type 3 Patients<\/p>\n    <\/a>\n\n<\/div><\/li><li class=\"wp-block-post post-1973 post type-post status-publish format-standard has-post-thumbnail hentry category-actualites-des-compagnies-du-portefeuille\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/thryv-therapeutics-granted-fda-orphan-drug-designation-for-lqt-1213-in-long-qt-syndrome-treatment\/\" title=\"Thryv Therapeutics Granted FDA Orphan Drug Designation for LQT-1213 in Long QT Syndrome Treatment\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1199\" height=\"628\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/thryv-therapeutics-fr-1-1758136900.png\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Actualit\u00e9s des compagnies du portefeuille \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">10.02.2024<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">Thryv Therapeutics Granted FDA Orphan Drug Designation for LQT-1213 in Long QT Syndrome Treatment<\/p>\n    <\/a>\n\n<\/div><\/li><li class=\"wp-block-post post-1976 post type-post status-publish format-standard has-post-thumbnail hentry category-actualites-dadmare\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/admare-bioinnovations-nomme-marc-riviere-a-son-conseil-dadministration\/\" title=\"adMare BioInnovations nomme Marc Rivi\u00e8re \u00e0 son conseil d\u2019administration\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1199\" height=\"628\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/marc-riviere-fr-1726843994.png\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Actualit\u00e9s d\u2019adMare \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">09.20.2024<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">adMare BioInnovations nomme Marc Rivi\u00e8re \u00e0 son conseil d\u2019administration<\/p>\n    <\/a>\n\n<\/div><\/li><li class=\"wp-block-post post-1980 post type-post status-publish format-standard has-post-thumbnail hentry category-actualites-des-compagnies-du-portefeuille\"><div class=\"wp-block-group post-item\">\n    <a class=\"news-linked-card\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/nanovation-therapeutics-announces-multi-target-partnership-with-novo-nordisk-to-develop-genetic-medicines-targeting-cardiometabolic-and-rare-diseases\/\" title=\"NanoVation Therapeutics Announces Multi-Target Partnership with Novo Nordisk to Develop Genetic Medicines Targeting Cardiometabolic and Rare Diseases\" style=\"text-decoration: none;\">\n                    <figure class=\"wp-block-image\">\n                <img loading=\"lazy\" decoding=\"async\" width=\"1200\" height=\"628\" src=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/nanovation-therapeutics-fr-1728480875.png\" class=\"attachment-full size-full wp-post-image\" alt=\"\" \/>            <\/figure>\n                <div class=\"wp-block-group\" style=\"display:flex;justify-content: space-between;\">\n            <p class=\"has-xsmall-font-size has-block-color\" style=\"margin: 0\">\n                                    Actualit\u00e9s des compagnies du portefeuille \n                            <\/p>\n            <p class=\"has-xsmall-font-size has-black-color\" style=\"margin: 0\">09.18.2024<\/p>\n        <\/div>\n        <p class=\"post-title has-small-font-size has-black-color\" style=\"font-weight: 700;margin-top:var(--wp--preset--spacing--20)\">NanoVation Therapeutics Announces Multi-Target Partnership with Novo Nordisk to Develop Genetic Medicines Targeting Cardiometabolic and Rare Diseases<\/p>\n    <\/a>\n\n<\/div><\/li>\n\n<div class=\"is-layout-flex pagination-links has-large-font-size\" style=\"flex-wrap: nowrap; justify-content: center; grid-column: 1\/-1; padding-top: var(--wp--preset--spacing--50); margin-top: 0;\">\n\t\t<a class=\"previous disabled\" data-page=\"1\" href=\"\" aria-label=\"Page pr\u00e9c\u00e9dente\" title=\"Page pr\u00e9c\u00e9dente\">Previous<\/a>\n\n\t\t\t<a class=\"page-number active\" data-page=\"1\" href=\"\/fr\/wp-json\/wp\/v2\/pages\/682?_paged=1\" aria-label=\"Page 1\" title=\"Page 1\">1<\/a>\n\t\t\t<a class=\"page-number \" data-page=\"2\" href=\"\/fr\/wp-json\/wp\/v2\/pages\/682?_paged=2\" aria-label=\"Page 2\" title=\"Page 2\">2<\/a>\n\t\n\t\t<a class=\"next \" data-page=\"2\" href=\"\/fr\/wp-json\/wp\/v2\/pages\/682?_paged=2\" aria-label=\"Page suivante\" title=\"Page suivante\">Next<\/a>\n<\/div>\n\t\t<\/ul>\n\t<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":678,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"light-footer","meta":{"footnotes":""},"class_list":["post-682","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Actualit\u00e9s et perspectives | adMare<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Actualit\u00e9s et perspectives | adMare\" \/>\n<meta property=\"og:url\" content=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/\" \/>\n<meta property=\"og:site_name\" content=\"adMare\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-24T14:48:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/03\/Homepage-Gradient-flip-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"2561\" \/>\n\t<meta property=\"og:image:height\" content=\"1708\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/\",\"url\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/\",\"name\":\"Actualit\u00e9s et perspectives | adMare\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Homepage-Gradient-flip-1.png\",\"datePublished\":\"2026-02-02T14:51:01+00:00\",\"dateModified\":\"2026-03-24T14:48:19+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/#primaryimage\",\"url\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Homepage-Gradient-flip-1.png\",\"contentUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Homepage-Gradient-flip-1.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nouvelles et \u00e9v\u00e9nements\",\"item\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Actualit\u00e9s et perspectives\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/\",\"name\":\"adMare\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#organization\",\"name\":\"adMare\",\"url\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Logo-light.svg\",\"contentUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Logo-light.svg\",\"width\":915,\"height\":337,\"caption\":\"adMare\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Actualit\u00e9s et perspectives | adMare","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"fr_FR","og_type":"article","og_title":"Actualit\u00e9s et perspectives | adMare","og_url":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/","og_site_name":"adMare","article_modified_time":"2026-03-24T14:48:19+00:00","og_image":[{"width":2561,"height":1708,"url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/03\/Homepage-Gradient-flip-1.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/","url":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/","name":"Actualit\u00e9s et perspectives | adMare","isPartOf":{"@id":"https:\/\/admarebio.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/#primaryimage"},"image":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/#primaryimage"},"thumbnailUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/03\/Homepage-Gradient-flip-1.png","datePublished":"2026-02-02T14:51:01+00:00","dateModified":"2026-03-24T14:48:19+00:00","breadcrumb":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/#primaryimage","url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/03\/Homepage-Gradient-flip-1.png","contentUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/03\/Homepage-Gradient-flip-1.png"},{"@type":"BreadcrumbList","@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/admarebio.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Nouvelles et \u00e9v\u00e9nements","item":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/"},{"@type":"ListItem","position":3,"name":"Actualit\u00e9s et perspectives"}]},{"@type":"WebSite","@id":"https:\/\/admarebio.com\/fr\/#website","url":"https:\/\/admarebio.com\/fr\/","name":"adMare","description":"","publisher":{"@id":"https:\/\/admarebio.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/admarebio.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/admarebio.com\/fr\/#organization","name":"adMare","url":"https:\/\/admarebio.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/admarebio.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/03\/Logo-light.svg","contentUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/03\/Logo-light.svg","width":915,"height":337,"caption":"adMare"},"image":{"@id":"https:\/\/admarebio.com\/fr\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/pages\/682","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/comments?post=682"}],"version-history":[{"count":5,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/pages\/682\/revisions"}],"predecessor-version":[{"id":959,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/pages\/682\/revisions\/959"}],"up":[{"embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/pages\/678"}],"wp:attachment":[{"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/media?parent=682"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}